biontech news - Search News

BioNTech, ADR

BioNTech SE ADR rises Monday, outperforms market

The BioNTech SE ADR BNTX inched 0.69% higher to $113.05 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.28% to 5,718.57 and the Dow Jones Industrial Average DJIA rising 0.

Business Insider · 5d

UBS Keeps Their Hold Rating on BioNTech SE (BNTX)

UBS analyst Eliana Merle maintained a Hold rating on BioNTech SE (BNTX – Research Report) today and set a price target of $131.00. The

Fintel on MSN · 6d

Jefferies Upgrades BioNTech SE - Depositary Receipt () (BNTX)

Fintel reports that on September 17, 2024, Jefferies upgraded their outlook for BioNTech SE - Depositary Receipt () (NasdaqGS:BNTX) from Hold to Buy. Analyst Price Forecast Suggests 8.06% Downside As of August 25,

MarketWatch · 3d

BioNTech SE ADR falls Friday, underperforms market

The BioNTech SE ADR BNTX shed 0.20% to $112.28 Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average DJIA rising 0.09% to 42,063.

4don MSN

BioNTech Is More Than a Covid-19 Stock. It’s Having a Great September.

BioNTech has been boosted a wave of enthusiasm over another company’s cancer drug, which has turned the biopharma industry ...

Zacks.com on MSN10h

PFE & BNTX Get Positive CHMP Opinion for Updated COVID-19 Jab

PFE along with BioNTech SE BNTX announced that the Committee for Medicinal Products for Human Use (CHMP) of the European ...

Business Insider17h

BioNTech SE (BNTX) Receives a Hold from Morgan Stanley

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on BioNTech SE (BNTX – Research Report), with a price target of $93.00. The company’s shares closed last Friday ...

Assembly Biosciences' Investigational Herpes Treatment Shows Antiviral Efficacy, Safety In Healthy Participants

Assembly Biosciences reported interim results from its Phase 1a study of ABI-5366, a long-acting HSV inhibitor for recurrent ...

12d

BioNTech's Low Valuation, Many Shots On Goal Make It A Buy

BioNTech shares surged 13% after Summit Therapeutics reported positive data on ivonescimab. Find out why BNTX stock is a Buy.

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union

Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and ...

10d

Forecasting The Future: 8 Analyst Projections For BioNTech

BioNTech BNTX has been analyzed by 8 analysts in the last three months, revealing a diverse range of perspectives from ...

Pharmabiz19h

EMA’s human medicines committee recommends marketing approval for Pfizer & BioNTech’s Omicron KP.2-adapted Covid-19 vaccine

EMA’s human medicines committee recommends marketing approval for Pfizer & BioNTech’s Omicron KP.2-adapted Covid-19 vaccine: New York Monday, September 23, 2024, 10:00 Hrs [IS ...